N-Side

Executive Summary

N-SIDE is a Belgian digital health company that leverages AI-driven forecasting, planning, and optimization solutions to streamline clinical trial supply chains. Founded in 2000, the company combines advanced analytics and machine learning with deep domain expertise to help pharmaceutical companies accelerate the delivery of innovative treatments to patients. By addressing the complex logistics of clinical trial materials, N-SIDE enables greater efficiency, reduced waste, and improved control over supply chain operations. Its platform brings clarity to an often opaque process, positioning the company as a key enabler in the clinical trial value chain. As the pharmaceutical industry increasingly adopts digital tools to cut costs and shorten development timelines, N-SIDE's solutions are well-aligned with market needs. Given its established track record and focus on AI optimization, N-SIDE is well-positioned for growth. The company's private status and lack of disclosed funding suggest it may be bootstrapped or conservatively financed. However, the increasing complexity of global clinical trials and the push toward decentralized models create significant tailwinds. N-SIDE's ability to integrate with existing systems and provide real-time insights makes it a valuable partner for sponsors and CROs. With a strong base in Europe and potential expansion into North America and Asia, the company could see heightened interest from strategic investors or acquirers. Its conviction score is moderate, reflecting a solid business model but limited public information on financial performance or competitive positioning.

Upcoming Catalysts (preview)

• Q4 2026Major Platform Upgrade or New Product Launch Targeting Decentralized Trials60% success
• Q2 2027Strategic Partnership with a Top-20 Pharma Company for Supply Chain Optimization50% success
• Q1 2027Series B or Later Equity Funding Round to Accelerate Expansion55% success